Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir pharmacokinetics with rifampicin in children with HIV and tuberculosis
PACTR202008554705202Phase 4Not yet recruiting
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dolutegravir and rifampicin in human immunodeficiency virus infection (HIV) and Tuberculosis (TB) (2 arms). Primary endpoints: Dolutegravir pharmacokinetics during rifampicin therapy and Population pharmacokinetic parameters. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
dolutegravirrifampicin
03
Conditions
human immunodeficiency virus infection (HIV)Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202008554705202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202008554705202.